Andrew Hollman Meyer - 02 Jan 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
02 Jan 2025
Net transactions value
-$731,785
Form type
4
Filing time
03 Jan 2025, 17:10:04 UTC
Previous filing
20 Dec 2024
Next filing
05 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Award $0 +18,000 +23% $0.000000 95,473 02 Jan 2025 Direct F1
transaction JANX Common Stock Sale $157,081 -2,922 -3.1% $53.76 92,551 02 Jan 2025 Direct F2, F3
transaction JANX Common Stock Sale $314,420 -5,768 -6.2% $54.51 86,783 02 Jan 2025 Direct F2, F4
transaction JANX Common Stock Sale $192,033 -3,444 -4% $55.76 83,339 02 Jan 2025 Direct F2, F5
transaction JANX Common Stock Sale $56,778 -1,000 -1.2% $56.78 82,339 02 Jan 2025 Direct F2, F6
transaction JANX Common Stock Sale $11,473 -200 -0.24% $57.36 82,139 02 Jan 2025 Direct F2, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock option (right to buy) Award $0 +63,000 $0.000000 63,000 02 Jan 2025 Common Stock 63,000 $53.24 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.
F2 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
F3 The weighted average sale price for the transaction reported was $53.7582 and the range of prices were between $53.20 and $54.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 The weighted average sale price for the transaction reported was $54.5111 and the range of prices were between $54.21 and $55.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5 The weighted average sale price for the transaction reported was $55.7587 and the range of prices were between $55.24 and $56.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F6 The weighted average sale price for the transaction reported was $56.7778 and the range of prices were between $56.33 and $57.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F7 The weighted average sale price for the transaction reported was $57.365 and the range of prices were between $57.35 and $57.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F8 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.